Aldeyra's Reproxalap Faces FDA Rejection, Stock Plummets
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jul 11 2025
0mins
Should l Buy ALDX?
Source: TipRanks
Aldeyra Therapeutics Inc's stock plummeted approximately 75% in premarket trading as it hit a 52-week low following another FDA rejection of its lead drug reproxalap.
The FDA issued a Complete Response Letter indicating that the New Drug Application for reproxalap lacked substantial evidence of efficacy in treating dry eye disease, raising significant concerns about the reliability of clinical trial findings. This marks the third rejection for reproxalap, which has faced ongoing challenges in demonstrating effectiveness in controlled studies. Aldeyra plans to request a Type A meeting with the FDA to discuss the next steps for approval, which could have critical implications for its drug development strategy.
The repeated failures in obtaining FDA approval have led to extreme market pessimism regarding Aldeyra's future prospects, significantly impacting investor confidence and raising questions about the company's ability to secure future financing and continue its research efforts.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALDX
Wall Street analysts forecast ALDX stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 1.800
Low
9.00
Averages
9.50
High
10.00
Current: 1.800
Low
9.00
Averages
9.50
High
10.00
About ALDX
Aldeyra Therapeutics, Inc. is a biotechnology company focused on discovering therapies designed to treat immune-mediated and metabolic diseases. The Company's approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Its product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX 248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Its late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of retinitis pigmentosa. ADX 629 is in Phase II clinical trials for moderate alcohol-associated hepatitis and Sjogren-Larsson Syndrome.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Lawsuit Filed Against Aldeyra Therapeutics
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has initiated a class action lawsuit against Aldeyra Therapeutics and certain executives, seeking damages for investors who purchased securities between November 3, 2023, and March 16, 2026, reflecting strong investor concerns over potential fraud.
- Allegations Details: The complaint alleges that defendants made false or misleading statements during the class period and failed to disclose inconsistencies in clinical trial results for the drug candidate reproxalap, leading to misjudgments about the company's prospects and impacting stock price stability.
- Investor Actions: Affected investors are encouraged to apply to be lead plaintiffs by May 29, 2026, to share in any potential recovery, indicating active participation and advocacy for their rights within the legal process.
- Legal Fee Arrangement: Bronstein, Gewirtz & Grossman, LLC will represent investors on a contingency fee basis, meaning they will only charge fees if they successfully recover damages, thus reducing financial risk for investors and encouraging more victims to join the lawsuit.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, to apply as lead plaintiffs by May 29, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Aldeyra made false and misleading statements regarding the inconsistent results of its drug candidate reproxalap's clinical trials, which led to investor losses when the true details emerged, negatively impacting the company's reputation and market confidence.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its successful track record and expertise in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that act merely as intermediaries, to ensure effective legal representation and support in the class action.
See More
Aldeyra Therapeutics Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Aldeyra Therapeutics is facing a securities fraud class action lawsuit for failing to disclose inconsistent results from its drug candidate reproxalap clinical trials, affecting investors from November 3, 2023, to March 16, 2026, highlighting significant transparency issues within the company.
- FDA Response: On March 17, 2026, Aldeyra received a Complete Response Letter from the FDA indicating a lack of substantial evidence supporting the drug's efficacy in treating dry eye disease, leading to a substantial decline in investor confidence regarding the company's future prospects.
- Stock Price Plunge: Following the lawsuit announcement, Aldeyra's stock price plummeted from $4.23 on March 16, 2026, to $1.24, representing a 71% drop, reflecting serious market concerns over the company's potential legal risks and product effectiveness.
- Investor Action: Affected investors must apply for lead plaintiff status by May 29, 2026, to represent the class in the lawsuit, emphasizing the importance of timely action to protect their rights and interests.
See More
Aldeyra Therapeutics Securities Fraud Class Action Reminder
- Lawsuit Background: A class action lawsuit has been filed on behalf of investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, alleging that the company failed to disclose inconsistencies in the clinical trial results of its drug candidate reproxalap, leading to significant investor losses.
- FDA Response: On March 17, 2026, Aldeyra received a Complete Response Letter from the FDA, indicating a lack of substantial evidence supporting the drug's efficacy in treating dry eye disease, with serious concerns raised about the reliability of the positive findings due to inconsistent trial results.
- Stock Price Plunge: Following the FDA announcement, Aldeyra's stock price plummeted from $4.23 per share on March 16, 2026, to $1.24, representing a decline of approximately 71%, which has severely impacted investor confidence.
- Investor Action: Investors are urged to apply for lead plaintiff status by May 29, 2026, to represent other investors in the lawsuit, as failing to submit applications by this deadline will result in the loss of the opportunity to participate in the litigation.
See More
Faruqi & Faruqi Encourages Investors in Aldeyra to Reach Out
- Legal Investigation: Faruqi & Faruqi LLP is investigating potential claims against Aldeyra Therapeutics, Inc., particularly for investors who purchased securities between November 3, 2023, and March 16, 2026, urging them to seek lead plaintiff status by the May 29, 2026 deadline.
- FDA Rejection: On March 17, 2026, Aldeyra disclosed that the FDA issued a Complete Response Letter rejecting its NDA for reproxalap due to insufficient evidence of efficacy, causing the stock price to plummet by 70.7% to close at $1.24 per share, indicating severe market skepticism regarding the product's effectiveness.
- False Statement Allegations: The lawsuit alleges that Aldeyra and its executives violated federal securities laws by making false and/or misleading statements despite inconsistent clinical trial results, leading to investor losses once the true information was revealed, highlighting significant governance and transparency issues within the company.
- Investor Rights Protection: Faruqi & Faruqi encourages anyone with information regarding Aldeyra's conduct, including whistleblowers and former employees, to contact the firm to provide legal support for affected investors, ensuring their rights are protected.
See More
Class Action Filed Against Aldeyra Therapeutics for Misleading Investors
- Class Action Initiated: Robbins LLP has reminded all investors who purchased Aldeyra Therapeutics (NASDAQ:ALDX) securities between November 3, 2023, and March 16, 2026, that a class action has been filed, alleging the company misled investors regarding clinical trial results, significantly impacting investment decisions.
- Inconsistent Clinical Trial Results: The lawsuit claims that Aldeyra failed to disclose the inconsistency of results from its lead drug candidate reproxalap's clinical trials, rendering any positive findings unreliable and severely affecting the company's business outlook.
- Stock Price Plummet: Following the receipt of a Complete Response Letter from the SEC on March 17, 2026, indicating a lack of substantial evidence for the drug's efficacy, Aldeyra's stock price fell by $2.99, or approximately 70.7%, closing at $1.24 per share, reflecting extreme market pessimism regarding the company's future.
- Shareholder Action Guidance: Shareholders are advised to submit their papers by May 29, 2026, if they wish to serve as lead plaintiffs in the class action, emphasizing the importance of corporate governance and executive accountability, with the option to remain absent from the case while still being eligible for recovery.
See More
Class Action Lawsuit Filed Against Aldeyra Therapeutics
- Lawsuit Background: Bronstein, Gewirtz & Grossman, LLC has initiated a class action lawsuit against Aldeyra Therapeutics and certain executives, seeking damages for investors who purchased securities between November 3, 2023, and March 16, 2026, reflecting strong investor concerns over potential fraud.
- Allegations Details: The complaint alleges that defendants made false or misleading statements during the class period and failed to disclose inconsistencies in clinical trial results for the drug candidate reproxalap, leading to misjudgments about the company's prospects and impacting stock price stability.
- Investor Actions: Affected investors are encouraged to apply to be lead plaintiffs by May 29, 2026, to share in any potential recovery, indicating active participation and advocacy for their rights within the legal process.
- Legal Fee Arrangement: Bronstein, Gewirtz & Grossman, LLC will represent investors on a contingency fee basis, meaning they will only charge fees if they successfully recover damages, thus reducing financial risk for investors and encouraging more victims to join the lawsuit.
See More
Reminder of Aldeyra Securities Class Action
- Class Action Notice: Rosen Law Firm reminds investors who purchased Aldeyra Therapeutics (NASDAQ: ALDX) securities between November 3, 2023, and March 16, 2026, to apply as lead plaintiffs by May 29, 2026, to potentially receive compensation without any out-of-pocket costs.
- Lawsuit Background: The lawsuit alleges that Aldeyra made false and misleading statements regarding the inconsistent results of its drug candidate reproxalap's clinical trials, which led to investor losses when the true details emerged, negatively impacting the company's reputation and market confidence.
- Law Firm Credentials: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, being ranked first by ISS Securities Class Action Services in 2017, showcasing its successful track record and expertise in this field.
- Investor Guidance: Investors are advised to carefully select qualified counsel with a proven track record, avoiding firms that act merely as intermediaries, to ensure effective legal representation and support in the class action.
See More
Aldeyra Therapeutics Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: Aldeyra Therapeutics is facing a securities fraud class action lawsuit for failing to disclose inconsistent results from its drug candidate reproxalap clinical trials, affecting investors from November 3, 2023, to March 16, 2026, highlighting significant transparency issues within the company.
- FDA Response: On March 17, 2026, Aldeyra received a Complete Response Letter from the FDA indicating a lack of substantial evidence supporting the drug's efficacy in treating dry eye disease, leading to a substantial decline in investor confidence regarding the company's future prospects.
- Stock Price Plunge: Following the lawsuit announcement, Aldeyra's stock price plummeted from $4.23 on March 16, 2026, to $1.24, representing a 71% drop, reflecting serious market concerns over the company's potential legal risks and product effectiveness.
- Investor Action: Affected investors must apply for lead plaintiff status by May 29, 2026, to represent the class in the lawsuit, emphasizing the importance of timely action to protect their rights and interests.
See More
Aldeyra Therapeutics Securities Fraud Class Action Reminder
- Lawsuit Background: A class action lawsuit has been filed on behalf of investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, alleging that the company failed to disclose inconsistencies in the clinical trial results of its drug candidate reproxalap, leading to significant investor losses.
- FDA Response: On March 17, 2026, Aldeyra received a Complete Response Letter from the FDA, indicating a lack of substantial evidence supporting the drug's efficacy in treating dry eye disease, with serious concerns raised about the reliability of the positive findings due to inconsistent trial results.
- Stock Price Plunge: Following the FDA announcement, Aldeyra's stock price plummeted from $4.23 per share on March 16, 2026, to $1.24, representing a decline of approximately 71%, which has severely impacted investor confidence.
- Investor Action: Investors are urged to apply for lead plaintiff status by May 29, 2026, to represent other investors in the lawsuit, as failing to submit applications by this deadline will result in the loss of the opportunity to participate in the litigation.
See More
Faruqi & Faruqi Encourages Investors in Aldeyra to Reach Out
- Legal Investigation: Faruqi & Faruqi LLP is investigating potential claims against Aldeyra Therapeutics, Inc., particularly for investors who purchased securities between November 3, 2023, and March 16, 2026, urging them to seek lead plaintiff status by the May 29, 2026 deadline.
- FDA Rejection: On March 17, 2026, Aldeyra disclosed that the FDA issued a Complete Response Letter rejecting its NDA for reproxalap due to insufficient evidence of efficacy, causing the stock price to plummet by 70.7% to close at $1.24 per share, indicating severe market skepticism regarding the product's effectiveness.
- False Statement Allegations: The lawsuit alleges that Aldeyra and its executives violated federal securities laws by making false and/or misleading statements despite inconsistent clinical trial results, leading to investor losses once the true information was revealed, highlighting significant governance and transparency issues within the company.
- Investor Rights Protection: Faruqi & Faruqi encourages anyone with information regarding Aldeyra's conduct, including whistleblowers and former employees, to contact the firm to provide legal support for affected investors, ensuring their rights are protected.
See More
Class Action Filed Against Aldeyra Therapeutics for Misleading Investors
- Class Action Initiated: Robbins LLP has reminded all investors who purchased Aldeyra Therapeutics (NASDAQ:ALDX) securities between November 3, 2023, and March 16, 2026, that a class action has been filed, alleging the company misled investors regarding clinical trial results, significantly impacting investment decisions.
- Inconsistent Clinical Trial Results: The lawsuit claims that Aldeyra failed to disclose the inconsistency of results from its lead drug candidate reproxalap's clinical trials, rendering any positive findings unreliable and severely affecting the company's business outlook.
- Stock Price Plummet: Following the receipt of a Complete Response Letter from the SEC on March 17, 2026, indicating a lack of substantial evidence for the drug's efficacy, Aldeyra's stock price fell by $2.99, or approximately 70.7%, closing at $1.24 per share, reflecting extreme market pessimism regarding the company's future.
- Shareholder Action Guidance: Shareholders are advised to submit their papers by May 29, 2026, if they wish to serve as lead plaintiffs in the class action, emphasizing the importance of corporate governance and executive accountability, with the option to remain absent from the case while still being eligible for recovery.
See More
